Effects of Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients
Launched by POZNAN UNIVERSITY OF MEDICAL SCIENCES · Nov 1, 2012
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • PCO - Androgen Excess Society criteria: hyperandrogenism (hirsutism) / hyperandrogenemia (testosterone \>70ng/dl) and/or oligomenorrhea (\<8 spontaneous menses per year) and/or polycystic ovarian morphology on ultrasound
- • Normal prolactin, TSH, 17-OH progesterone
- • No evidence of androgen producing malignancy, Cushing's syndrome or acromegaly
- • Age 18-40
- Exclusion Criteria:
- • Use of oral contraceptives and/or other steroid hormones 3 months prior to the study
About Poznan University Of Medical Sciences
Poznań University of Medical Sciences is a leading academic institution dedicated to advancing medical education, research, and patient care. With a strong emphasis on clinical trials and innovative healthcare solutions, the university fosters a collaborative environment that integrates cutting-edge scientific inquiry with practical applications in medicine. By leveraging its extensive network of healthcare professionals and researchers, Poznań University of Medical Sciences aims to contribute significantly to the development of new therapies and improve health outcomes, ensuring that its clinical trials are conducted with the highest standards of ethics and scientific rigor.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Poznan, , Poland
Patients applied
Trial Officials
Leszek A Pawelczyk, MD PhD
Study Chair
Poznan University of Medical Sciences
Antoni J Duleba, MD
Study Director
University of California, Davis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials